The mechanism of STING agonists in combination with checkpoint inhibitors have been evaluated in various preclinical and clinical studies, revealing a synergistic effect that enhances anti-tumor responses [105,106]—even in tumors resistant to checkpoint blockade monotherapy [76,87,136]. Here, STING1 is linked to neoplasm.